Following U.S. and EU market authorization for Waskyra™, AGC Biologics will continue to support the commercial development of the gene therapy.

AGC Biologics signed a licensing agreement to use Asimov’s lentiviral packaging system, enabling production from a single-plasmid transfection.

With the decision by the U.S. Food and Drug Administration and the European Commission to grant market authorization for Waskyratm, a gene therapy to treat Wiskott-Aldrich syndrome, AGC Biologics' ...

Data indicate that the AutoCell platform could pave the way for CGTs for the first time as first-line therapies.

Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...

A novel lentiviral packaging system enables production from a single-plasmid transfection instead of the standard four-plasmid process.